Marea Therapeutics, a biotechnology enterprise focused on clinical-stage developments and backed by Third Rock Ventures, is dedicated to creating innovative treatments for cardiometabolic disorders.

Day One Enhances Pipeline with Innovative Clinical-Stage ADC Targeting PTK7 for Solid Tumors in Adults and Children.

This trial assesses SCB-1019, Clover’s bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine candidate, developed using the company’s proprietary Trimer-Tag vaccine technology platform.

Spyre Therapeutics Begins Phase 1 Trial with Initial Doses of SPY001, a New Long-acting anti-α4β7 Antibody, for Inflammatory Bowel Disease Treatment.

FDA has approved SKYRIZI® (risankizumab-rzaa) for treating ulcerative colitis, broadening AbbVie’s inflammatory bowel disease treatment options.

Sobi revealed that the European Commission has approved the Marketing Authorisation for ALTUVOCT™ (efanesoctocog alfa) for the treatment and prevention of bleeding episodes and perioperative prophylaxis in patients with haemophilia A.

KalVista Submits New Drug Application to FDA for Sebetralstat, the First Oral On-demand Treatment for Hereditary Angioedema.

Update on the CAPItello-290 Phase III study of Truqap combined with chemotherapy for advanced or metastatic triple-negative breast cancer.

NMD Pharma Gets FDA IND Approval to Start Phase 2 Study of NMD670 in US for Charcot-Marie-Tooth Disease.

Mozart Therapeutics Administers Initial Dose in Phase 1 Clinical Study of MTX-101 for Autoimmune Disease Therapy.

Zymeworks Receives FDA Approval for ZW171, a New Bispecific Antibody Targeting Mesothelin-related Tumors.

iTeos and GSK Launch Phase 3 GALAXIES Lung-301 Trial, Evaluating Belrestotug and Dostarlimab in Untreated, Inoperable Advanced/Metastatic PD-L1 Positive Non-Small Cell Lung Cancer.